Xilio Therapeutics, Inc.
General ticker "XLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $48.7M (TTM average)
Xilio Therapeutics, Inc. follows the US Stock Market performance with the rate: 8.1%.
Estimated limits based on current volatility of 2.3%: low 8.74$, high 9.15$
Factors to consider:
- Total employees count: 76 (+18.8%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Raw material shortages, Capital raising
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.00$, 17.84$]
- 2026-12-31 to 2027-12-31 estimated range: [3.78$, 12.14$]
Financial Metrics affecting the XLO estimates:
- Negative: with PPE of -1.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.65 <= 2.37
- Positive: -0.14 < Investing cash flow per share per price, % of -0.07
- Negative: negative Industry operating cash flow (median)
Short-term XLO quotes
Long-term XLO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $6.34MM | $43.77MM |
| Operating Expenses | $79.13MM | $66.93MM | $85.75MM |
| Operating Income | $-79.13MM | $-60.58MM | $-41.98MM |
| Non-Operating Income | $2.73MM | $2.34MM | $6.95MM |
| R&D Expense | $52.14MM | $41.21MM | $56.04MM |
| Income(Loss) | $-76.40MM | $-58.24MM | $-35.04MM |
| Net Income(Loss)* | $-76.40MM | $-58.24MM | $-35.04MM |
| Stockholders Equity | $36.83MM | $17.60MM | $35.27MM |
| Assets | $60.93MM | $71.08MM | $154.69MM |
| Operating Cash Flow | $-68.62MM | $-18.38MM | $-4.99MM |
| Capital expenditure | $0.49MM | $0.04MM | $0.52MM |
| Investing Cash Flow | $-0.49MM | $-0.04MM | $-0.52MM |
| Financing Cash Flow | $-6.55MM | $29.20MM | $87.78MM |
| Earnings Per Share** | $-38.90 | $-15.24 | $-4.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.